Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This is a multi-centre randomised, double blind, placebo-controlled, parallel group trial of the effectiveness of the nocturnal use of a Temperature Controlled Laminar Airflow (TLA) Device (Airsonett®) in adults with poorly-controlled, severe allergic asthma


The trial is assessing whether a new treatment device might help to reduce the frequency of severe asthma attacks in patients with allergic asthma.

Asthma affects over 5 million people in the UK. Half a million of these have a severe form of the condition. Potentially life threatening attacks, known as exacerbations, are a frequent occurrence. Current treatment options to reduce the frequency of these exacerbations are limited.

The LASER trial will evaluate the effectiveness of a new treatment – Temperature Controlled Laminar Airflow (TLA.) TLA is delivered by an Airsonett® machine. The machine is used overnight in the patient’s home at the bedside. The machine filters allergy particles from the air overnight, allowing patients to sleep and ‘rest’ their lungs.

Trial Publications

The primary results publication can be found here.

The protocol publication can be found here.